Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study.

IF 1.8 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

Medicina Oral Patologia Oral Y Cirugia Bucal Pub Date : 2024-03-01 DOI:10.4317/medoral.26237

J-O Martins, M-M Borges, C-E Malta, J-M Guerra, A-A Crispim, B-C Coelho, L-F Silva, P-G Silva

{"title":"Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study.","authors":"J-O Martins, M-M Borges, C-E Malta, J-M Guerra, A-A Crispim, B-C Coelho, L-F Silva, P-G Silva","doi":"10.4317/medoral.26237","DOIUrl":null,"url":null,"abstract":"Background: This study retrospectively analyzed the risk factors for oral mucositis (OM) during cetuximab treatment.Material and methods: We screened patients using cetuximab and retrospectively evaluated the presence of OM based on medical records. We collected information from 2 years of evaluations. Patient medical records were reviewed to obtain data on chemotherapy cycle and dose, sex, age, primary tumor, TNM stage, and head and neck radiotherapy (HNR) history. The X2 test and multinomial logistic regression were used for statistical analysis (SPSS 20.0, p < 0.05).Results: Among 1831 patients, OM was showed in 750 in any grade (41%), during cetuximab treatment. Most patients were female (n=944, 51.6%), <70years-old (n=1149, 62.8%), had larynx cancer (n=789, 43.1%) in T4 (n=579, 47.7%), N0 (n=509, 52.6%) stages. Primary tumor surgery was performed in 1476 (80.6%) patients, radiotherapy in 606 (33.1%) patients and cetuximab protocols most used involved up to four cycles (n=1072, 58.5%) of <400mg (n=996, 54.4%) cetuximab doses. Female (OR [odds ratio] = 2.17, CI95% = 1.26-3.75), >70 years-old patients (OR = 16.02, CI95% = 11.99-21.41), with HHNR (OR = 1.84, 1.41-2.40), treated with >4 cycles (OR = 1.52, CI95% = 1.16-2.01) and high doses of cetuximab (OR = 3.80, CI95% = 2.52-5.71) are the greatest risk factors for OM.Conclusions: Since the clinical benefit of cetuximab in the treatment of older patients is limited and there is a high OM, especially in women with head and neck treated with radiotherapy, high doses and a high number of cetuximab cycles must be administered with caution.","PeriodicalId":49016,"journal":{"name":"Medicina Oral Patologia Oral Y Cirugia Bucal","volume":" ","pages":"e248-e254"},"PeriodicalIF":1.8000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10945870/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Oral Patologia Oral Y Cirugia Bucal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4317/medoral.26237","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study retrospectively analyzed the risk factors for oral mucositis (OM) during cetuximab treatment.

Material and methods: We screened patients using cetuximab and retrospectively evaluated the presence of OM based on medical records. We collected information from 2 years of evaluations. Patient medical records were reviewed to obtain data on chemotherapy cycle and dose, sex, age, primary tumor, TNM stage, and head and neck radiotherapy (HNR) history. The X2 test and multinomial logistic regression were used for statistical analysis (SPSS 20.0, p < 0.05).

Results: Among 1831 patients, OM was showed in 750 in any grade (41%), during cetuximab treatment. Most patients were female (n=944, 51.6%), <70years-old (n=1149, 62.8%), had larynx cancer (n=789, 43.1%) in T4 (n=579, 47.7%), N0 (n=509, 52.6%) stages. Primary tumor surgery was performed in 1476 (80.6%) patients, radiotherapy in 606 (33.1%) patients and cetuximab protocols most used involved up to four cycles (n=1072, 58.5%) of <400mg (n=996, 54.4%) cetuximab doses. Female (OR [odds ratio] = 2.17, CI95% = 1.26-3.75), >70 years-old patients (OR = 16.02, CI95% = 11.99-21.41), with HHNR (OR = 1.84, 1.41-2.40), treated with >4 cycles (OR = 1.52, CI95% = 1.16-2.01) and high doses of cetuximab (OR = 3.80, CI95% = 2.52-5.71) are the greatest risk factors for OM.

Conclusions: Since the clinical benefit of cetuximab in the treatment of older patients is limited and there is a high OM, especially in women with head and neck treated with radiotherapy, high doses and a high number of cetuximab cycles must be administered with caution.

查看原文本刊更多论文

西妥昔单抗治疗的实体瘤患者口腔黏膜炎的危险因素:一项回顾性横断面研究。

背景:本研究回顾性分析西妥昔单抗治疗期间口腔黏膜炎(OM)的危险因素。材料和方法:我们使用西妥昔单抗筛选患者，并根据医疗记录回顾性评估OM的存在。我们从2年的评估中收集信息。研究人员回顾了患者的医疗记录，以获得化疗周期和剂量、性别、年龄、原发肿瘤、TNM分期和头颈部放疗(HNR)史等数据。采用X2检验和多项logistic回归进行统计学分析(SPSS 20.0, p < 0.05)。结果:在1831例患者中，在西妥昔单抗治疗期间，所有级别中有750例(41%)出现OM。大多数患者为女性(n=944, 51.6%)， 70岁患者(OR = 16.02, CI95% = 11.99 ~ 21.41)， HHNR (OR = 1.84, 1.41 ~ 2.40)，治疗周期>4个(OR = 1.52, CI95% = 1.16 ~ 2.01)和大剂量西妥昔单抗(OR = 3.80, CI95% = 2.52 ~ 5.71)是OM的最大危险因素。结论:由于西妥昔单抗治疗老年患者的临床获益有限，且存在较高的OM，特别是头颈部放疗的女性，因此必须谨慎使用高剂量和高周期的西妥昔单抗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicina Oral Patologia Oral Y Cirugia Bucal DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

4.60

自引率

0.00%

发文量

审稿时长

3-8 weeks

期刊介绍： 1. Oral Medicine and Pathology: Clinicopathological as well as medical or surgical management aspects of diseases affecting oral mucosa, salivary glands, maxillary bones, as well as orofacial neurological disorders, and systemic conditions with an impact on the oral cavity. 2. Oral Surgery: Surgical management aspects of diseases affecting oral mucosa, salivary glands, maxillary bones, teeth, implants, oral surgical procedures. Surgical management of diseases affecting head and neck areas. 3. Medically compromised patients in Dentistry: Articles discussing medical problems in Odontology will also be included, with a special focus on the clinico-odontological management of medically compromised patients, and considerations regarding high-risk or disabled patients. 4. Implantology 5. Periodontology